山东医药2017，Vol.57Issue(40)：5-8,4.DOI:10.3969/j.issn.1002-266X.2017.40.002
BRCA1、ERCC1、TYMS及TUBB3基因检测指导进展期胃癌个体化化疗效果观察
Effects of detection of BRCA1, ERCC1, TYMS and TUBB3 genes in guidance of individual chemotherapy for patients with advanced gastric cancer
摘要
Abstract
Objective To investigate the effects of detection of BRCA 1, ERCC1, TYMS and TUBB3 genes in guid-ance of individual chemotherapy for patients with advanced gastric cancer .Methods Eighty patients with advanced gastric cancer were randomly divided into the individual group (TG) (n=40) and the control group (CG) (n=40).The protein and mRNA expression levels of BRCA1, ERCC1, TYMS and TUBB3 genes were measured by immunohistochemical method and branched-DNA liquid chip quantitative analysis , respectively .Different chemotherapies were administered according to the mRNA expression levels of the four genes , while DCF or mDCF chemotherapy was directly applied to the control group . Overall response rate ( ORR) , adverse effects , and progression-free survival ( PFS) were observed and analyzed .Results After two cycles, ORR were 41.9%in the TG and 39.4%in the CG.KPS clinical benefit rates were 54.8%in the TG and 54.5%in the CG.There were no statistical differences between two groups (both P>0.05).After four cycles, ORR were 45%in the TG and 54.5%in the CG, and KPS clinical benefit rates were 75.0%in the TG and 72.7%in the CG. There were no statistical differences between two groups (both P>0.05).The rates of adverse effects in grade 3 to 4 were 26.3%and 55.9% in the TG and CG, respectively.There was no statistical difference between the two groups ( P>0.05), but adverse effects were significantly less serious in TG than in CG after dose reduction and chemotherapy discon -tinuance (P<0.05).PFS were 7.7 m (95%CI:5.97-9.42) and 6.6 m (95%CI:5.59-7.6) in the TG and CG.There was no statistically significant difference between the two groups (P>0.05).Conclusion Compared with DCF or mDCF chemotherapy, using their BRCA1, ERCC1, TYMS and TUBB3 mRNA expression levels in guidance of the individual chemotherapy for patients with advanced gastric cancer may reduce the adverse effects , but there are no statistical differ-ences in the ORR and PFS .关键词
胃癌/BRCA1基因/ERCC1基因/TYMS基因/TUBB3基因/药物疗法Key words
stomach carcinoma/BRCA1 gene/ERCC1 gene/TYMS gene/TUBB3 gene/pharmacotherapy分类
医药卫生引用本文复制引用
王琳,陈邓林,陈俊民,邢雪花,王海霞,黄琰菁,孙达统,杨生辉,盛莉,邱纯..BRCA1、ERCC1、TYMS及TUBB3基因检测指导进展期胃癌个体化化疗效果观察[J].山东医药,2017,57(40):5-8,4.基金项目
海南省自然科学基金资助项目(814315) （814315）
海南省卫生厅科研基金项目(琼卫2013 资助-088 号) （琼卫2013 资助-088 号）
海南省2014 年度留学人员科技活动项目择优资助经费项目 （）
海南省人民医院2013专项资助基金(自然科学类). （自然科学类）
